临床耳鼻咽喉头颈外科杂志
臨床耳鼻嚥喉頭頸外科雜誌
림상이비인후두경외과잡지
JOURNAL OF CLINICAL OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY
2009年
19期
881-883
,共3页
甲状腺肿瘤%淋巴转移%环氧化酶-2%血管内皮生长因子-C%免疫组织化学
甲狀腺腫瘤%淋巴轉移%環氧化酶-2%血管內皮生長因子-C%免疫組織化學
갑상선종류%림파전이%배양화매-2%혈관내피생장인자-C%면역조직화학
thyroid neoplasms%lymphatic metastasis%cyclooxygenase-2%vascular endothelial growth factor-c%immunohistochemistry
目的:探讨环氧化酶-2(COX-2)和血管内皮生长因子-C(VEGF-C)在甲状腺乳头状癌组织中的表达及与颈淋巴结转移的关系.方法:应用免疫组织化学方法检测40例甲状腺乳头状癌组织中COX-2和VEGF-C的表达情况,并进行颈淋巴结转移相关性分析.结果:甲状腺乳头状癌组织中COX-2和VEGF-C的表达阳性率分别为70.0%(28/40)和75.0%(30/40),其中颈淋巴结转移组COX-2和VEGF-C的表达阳性率分别为80.8%(21/26)和84.6%(22/26),无颈淋巴结转移组分别为50.0%(7/14)和57.1%(8/14),两组之间差异均有统计学意义(P＜0.05).甲状腺乳头状癌组织中COX-2和VEGF-C之间表达呈正相关(r＝0.378,P＜0.05).结论:COX-2和VEGF-C在甲状腺乳头状癌组织中高表达且关系密切,两者在甲状腺乳头状癌颈淋巴结转移中发挥作用且可能有协同效应.
目的:探討環氧化酶-2(COX-2)和血管內皮生長因子-C(VEGF-C)在甲狀腺乳頭狀癌組織中的錶達及與頸淋巴結轉移的關繫.方法:應用免疫組織化學方法檢測40例甲狀腺乳頭狀癌組織中COX-2和VEGF-C的錶達情況,併進行頸淋巴結轉移相關性分析.結果:甲狀腺乳頭狀癌組織中COX-2和VEGF-C的錶達暘性率分彆為70.0%(28/40)和75.0%(30/40),其中頸淋巴結轉移組COX-2和VEGF-C的錶達暘性率分彆為80.8%(21/26)和84.6%(22/26),無頸淋巴結轉移組分彆為50.0%(7/14)和57.1%(8/14),兩組之間差異均有統計學意義(P＜0.05).甲狀腺乳頭狀癌組織中COX-2和VEGF-C之間錶達呈正相關(r＝0.378,P＜0.05).結論:COX-2和VEGF-C在甲狀腺乳頭狀癌組織中高錶達且關繫密切,兩者在甲狀腺乳頭狀癌頸淋巴結轉移中髮揮作用且可能有協同效應.
목적:탐토배양화매-2(COX-2)화혈관내피생장인자-C(VEGF-C)재갑상선유두상암조직중적표체급여경림파결전이적관계.방법:응용면역조직화학방법검측40례갑상선유두상암조직중COX-2화VEGF-C적표체정황,병진행경림파결전이상관성분석.결과:갑상선유두상암조직중COX-2화VEGF-C적표체양성솔분별위70.0%(28/40)화75.0%(30/40),기중경림파결전이조COX-2화VEGF-C적표체양성솔분별위80.8%(21/26)화84.6%(22/26),무경림파결전이조분별위50.0%(7/14)화57.1%(8/14),량조지간차이균유통계학의의(P＜0.05).갑상선유두상암조직중COX-2화VEGF-C지간표체정정상관(r＝0.378,P＜0.05).결론:COX-2화VEGF-C재갑상선유두상암조직중고표체차관계밀절,량자재갑상선유두상암경림파결전이중발휘작용차가능유협동효응.
Objective:To investigate the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor-C (VEGF-C) in papillary thyroid carcinoma and their relationship to cervical lymph metastases.Method:In this study, the expressions of COX-2 and VEGF-C were examined by immunohistochemistry in papillary thyroid carcinoma tissues of 40 patients, and analysis was performed on the correlation of cervical lymph metastases with COX-2 and VEGF-C expression.Result:Positive expressions of COX-2 and VEGF-C were 70.0%(28/40)and 75.0%(30/40)respectively in papillary thyroid carcinoma. The positive rates of COX-2 and VEGF-C expression were 80.8%(21/26)and 84.6%(22/26)respectively in patients with cervical lymph metastases, and 50.0%(7/14)and 57.1%(8/14)respectively in patients without cervical lymph metastases, with a statistically significant difference between two groups(P<0.05, all). COX-2 was positively correlated to VEGF-C expression in papillary thyroid carcinoma(r=0.378, P<0.05).Conclusion:The results suggest that COX-2 and VEGF-C were highly expressed in papillary thyroid carcinoma, with possible interaction of their expressions, and may play a critical role in the cervical lymph metastases of papillary thyroid carcinoma.
